Radboud university medical center study sets new milestone with 90% diagnostic accuracy of lung nodules suspected of cancer using Philips technology for bronchoscopic procedures
On October 4, 2021, Radboud university medical center announced a significant achievement in lung cancer diagnostics using Philips technology. The clinical study reported a 90% diagnostic accuracy in identifying lung cancer through navigation bronchoscopy, leveraging the Philips Lung Suite and Azurion system. Additionally, the average radiation dose per procedure was reduced by over half, from 47.5 Gy·cm2 to 25.4 Gy·cm2. This advancement marks a potential turning point in early lung cancer detection, significant given the high mortality rate associated with the disease.
- Achieved 90% diagnostic accuracy in lung cancer detection.
- Reduced average radiation dose per procedure by over 50%.
- Potential to set new standards for early detection and treatment of lung cancer.
- None.
October 4, 2021
Radboud university medical center study sets new milestone with
Hospital achieves world-first level of improvement in the diagnostic accuracy of navigation bronchoscopy using Philips Lung Suite combined with the company’s Image Guided Therapy System – Azurion
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Radboud university medical center (Radboudumc), a leading Dutch academic research and teaching hospital (Nijmegen, the Netherlands), have announced the positive results of a clinical study conducted by Radboudumc aimed at setting a new standard of safety and accuracy in the diagnosis of small peripheral lung lesions. The study outcomes represent a promising milestone in the global innovation effort to set a new clinical standard for detecting lung cancer at an early stage, potentially leading to improved prognoses for patients.
Radboudumc’s observational study reported the diagnostic accuracy and procedural radiation dose for patients undergoing an endobronchial lung biopsy supported by Philips Lung Suite - a solution that uses 3D imaging with augmented fluoroscopy to support high precision diagnosis and minimally-invasive therapy in one room. Diagnostic accuracy of
“The airways and lungs are very challenging places to biopsy, so we need good navigation to make sure we reach the target location,” said Dr. Erik van der Heijden, Pulmonologist and Associate Professor of Interventional Pulmonary Diseases at Radboudumc, who led the study. “Philips’ 3D imaging solution allows us to create real-time 3D visualizations enabling us to follow the correct path from different angles to where we need to be, which is particularly useful for very small abnormalities. Our study confirmed that it increases the accuracy and safety of the biopsy procedure, improving results for patients. Philips’ technology also offers the promising outlook that we could not only diagnose but also immediately treat these early-stage patients using novel procedures such as tumor ablation.”
Lung cancer – the leading cause of cancer death
Lung cancer kills around 1.7 million people a year worldwide. That makes it the leading cause of cancer death globally [2], accounting for greater loss of life than breast, colon, and prostate cancer combined. While early diagnosis and treatment are critical to better outcomes and quality of life, the majority of lung cancers are currently diagnosed at a late stage, with minimal chance of a surgical cure.
Early detection and diagnosis key to survivability
The research being carried out at Radboudumc focuses on the diagnosis of early-stage lung cancer lesions, typically detected during routine screening of high-risk patient groups or discovered and reported as so-called ‘incidental findings’ when a patient has a chest scan for some other reason. A tissue sample typically then needs to be obtained that a pathologist can use to make a definitive diagnosis.
Challenging for clinicians to accurately navigate
A new method is image-guided endobronchial lung biopsy, during which a clinician uses live image guidance to maneuver through the airways in the lungs to advance a catheter towards the lesion. However, the airways in the lungs are a complex network that requires accurate navigation to remove the required tissue sample. Until now, image-guided endobronchial lung biopsy has only really been effective when an abnormality or tumor is located in or near one of the larger airways in the lungs, and even then it is challenging for clinicians to accurately navigate when looking at a 2D greyscale fluoroscopy image while the lungs are moving as the patient breathes.
Philips Lung Suite enables all-in-one lung cancer diagnosis and treatment. It provides advanced real-time 3D imaging with augmented fluoroscopy on the company’s Image Guided Therapy System – Azurion, combined with dedicated software. With Philips’ Cone Beam CT imaging, the X-ray detector rotates around the patient to generate a CT-like image in around five seconds, providing clinicians with a high-resolution 3D view of the target lesion and other anatomical structures. This allows the clinician performing the biopsy procedure to be continually guided by high-quality real-time imaging to advance a catheter towards the lesion through a bronchoscope. Once done, its position can be confirmed in real-time using the same imaging modality and a biopsy sample removed.
Philips has a comprehensive portfolio of lung cancer diagnosis and treatment solutions. In addition to Philips Lung Suite, the company’s Lung Cancer Orchestrator provides an integrated lung cancer patient management system for both CT lung screening programs and incidental pulmonary findings programs that manages and monitors patients every step of the way in their lung cancer screening and treatment decision journey.
Read this interview with Dr. Erik van der Heijden on his personal experiences using Philips 3D imaging and navigation platform during image-guided endobronchial lung biopsy.
[1] Journal of Bronchology & Interventional Pulmonology: October 2021 - Volume 28 - Issue 4 - p 262-271 doi: 10.1097/LBR.0000000000000783
[2] CA CANCER J CLIN 2021;71:7–33, Cancer Statistics 2021: https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21654
For further information, please contact:
Joost Maltha
Philips Global Press Office
Tel: +31 610 558 116
Email: joost.maltha@philips.com
Fabienne van der Feer
Philips Image Guided Therapy
Tel: +31 622 698 001
Email: fabienne.van.der.feer@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at http://www.philips.com/newscenter
Attachments
- Dr. Erik van der Heijden Radboudumc Nijmegen
- Lung biopsy using Philips 3D navigation - 1
- Lung biopsy using Philips 3D navigation - 2
FAQ
What is the diagnostic accuracy reported in the recent Philips study on lung cancer?
How much was the radiation dose reduced in the Philips Lung Suite procedure?
When was the milestone study on lung cancer diagnostics announced?
What technology was used in the Radboud university medical center study?
What is the significance of early detection in lung cancer?
